Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph…
Background: Adoptive tumor-infiltrating lymphocytes (TIL) therapy and interleukin-2 (IL-2) have been investigated in melanoma.
Aim: To confirm previously observed preventive effects of TIL + IL2 in a subgroup of patients with relapsing metastatic stage III melanoma.
- Ref: doi: 10.1007/s00262-020-02572-1
- Année de publication : 2020
- Auteurs : Khammari A, Nguyen JM, Leccia MT, Guillot B, Saiagh S, Pandolfino MC, Knol AC, Quéreux G, Chiffolettau A, Labarrière N, Dréno B.
- Réseaux : Réseaux: « Immunothérapies »